早期suPAR水平作为COVID-19严重程度的预测指标：一种高效患者分诊的新工具

IF 2.2 4区医学 Q2 INFECTIOUS DISEASES

Infectious diseases now Pub Date : 2025-03-16 DOI:10.1016/j.idnow.2025.105058

Pauline Nègre , Didier Tayac , Thibaut Jamme , Marie-Sophie Combis , Françoise Maupas-Schwalm

{"title":"早期suPAR水平作为COVID-19严重程度的预测指标：一种高效患者分诊的新工具","authors":"Pauline Nègre , Didier Tayac , Thibaut Jamme , Marie-Sophie Combis , Françoise Maupas-Schwalm","doi":"10.1016/j.idnow.2025.105058","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Following several waves of the COVID-19 pandemic, we are now facing a lower but persistent rate of SARS-CoV-2 infections, with seasonal resurgences often coinciding with other respiratory tract infections.</div></div><div><h3>Objective</h3><div>We aimed to identify early clinico-biological variables predictive of an unfavorable outcome in patients with primary SARS-CoV-2 infection. We also evaluated the role of suPAR, an innovative biomarker, in predicting disease severity.</div></div><div><h3>Methods</h3><div>We included 255 patients with PCR-confirmed primary SARS-CoV-2 infection and with a 30-day follow-up minimum. Blood samples were collected within the first 24 h of hospitalization to measure suPAR levels. Comprehensive data from medical records were analyzed to assess their predictive value in stratifying patients into seven severity groups, with groups 1 to 3 representing severe COVID-19 (death, intubation, ECMO, or non-invasive ventilation).</div></div><div><h3>Results</h3><div>Early plasma suPAR levels were significantly associated with severe disease progression, as evidenced by ANOVA and logistic regression models, highlighting suPAR as a persistent predictive factor for unfavorable outcomes.</div></div><div><h3>Conclusion</h3><div>Our findings suggest that a single suPAR measurement, performed early after a positive PCR test for SARS-CoV-2, holds strong predictive value for patient outcomes. This biomarker, alongside pulse oximetry and CT scan results, could be instrumental in early patient triage during seasonal COVID-19 resurgences.</div></div>","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"55 4","pages":"Article 105058"},"PeriodicalIF":2.2000,"publicationDate":"2025-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Early suPAR levels as a predictor of COVID-19 severity: A new tool for efficient patient triage\",\"authors\":\"Pauline Nègre , Didier Tayac , Thibaut Jamme , Marie-Sophie Combis , Françoise Maupas-Schwalm\",\"doi\":\"10.1016/j.idnow.2025.105058\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Following several waves of the COVID-19 pandemic, we are now facing a lower but persistent rate of SARS-CoV-2 infections, with seasonal resurgences often coinciding with other respiratory tract infections.</div></div><div><h3>Objective</h3><div>We aimed to identify early clinico-biological variables predictive of an unfavorable outcome in patients with primary SARS-CoV-2 infection. We also evaluated the role of suPAR, an innovative biomarker, in predicting disease severity.</div></div><div><h3>Methods</h3><div>We included 255 patients with PCR-confirmed primary SARS-CoV-2 infection and with a 30-day follow-up minimum. Blood samples were collected within the first 24 h of hospitalization to measure suPAR levels. Comprehensive data from medical records were analyzed to assess their predictive value in stratifying patients into seven severity groups, with groups 1 to 3 representing severe COVID-19 (death, intubation, ECMO, or non-invasive ventilation).</div></div><div><h3>Results</h3><div>Early plasma suPAR levels were significantly associated with severe disease progression, as evidenced by ANOVA and logistic regression models, highlighting suPAR as a persistent predictive factor for unfavorable outcomes.</div></div><div><h3>Conclusion</h3><div>Our findings suggest that a single suPAR measurement, performed early after a positive PCR test for SARS-CoV-2, holds strong predictive value for patient outcomes. This biomarker, alongside pulse oximetry and CT scan results, could be instrumental in early patient triage during seasonal COVID-19 resurgences.</div></div>\",\"PeriodicalId\":13539,\"journal\":{\"name\":\"Infectious diseases now\",\"volume\":\"55 4\",\"pages\":\"Article 105058\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2025-03-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Infectious diseases now\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666991925000375\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious diseases now","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666991925000375","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

摘要

在经历了几波COVID-19大流行之后，我们现在面临着较低但持续的SARS-CoV-2感染率，季节性复发往往与其他呼吸道感染同时发生。目的：我们旨在确定可预测原发性SARS-CoV-2感染患者不良结局的早期临床生物学变量。我们还评估了suPAR（一种创新的生物标志物）在预测疾病严重程度中的作用。方法纳入255例经pcr确诊的原发性SARS-CoV-2感染患者，随访时间至少为30天。在住院前24小时内采集血样以测量suPAR水平。对医疗记录的综合数据进行分析，以评估其在将患者分为七个严重程度组中的预测价值，其中1至3组代表严重的COVID-19（死亡、插管、ECMO或无创通气）。ANOVA和logistic回归模型证明，早期血浆suPAR水平与严重疾病进展显著相关，表明suPAR是不利结果的持续预测因素。结论：我们的研究结果表明，在SARS-CoV-2 PCR检测阳性后早期进行单次suPAR测量对患者预后具有很强的预测价值。这种生物标志物与脉搏血氧仪和CT扫描结果一起，可能有助于在COVID-19季节性复发期间对患者进行早期分诊。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Early suPAR levels as a predictor of COVID-19 severity: A new tool for efficient patient triage

Background

Following several waves of the COVID-19 pandemic, we are now facing a lower but persistent rate of SARS-CoV-2 infections, with seasonal resurgences often coinciding with other respiratory tract infections.

Objective

We aimed to identify early clinico-biological variables predictive of an unfavorable outcome in patients with primary SARS-CoV-2 infection. We also evaluated the role of suPAR, an innovative biomarker, in predicting disease severity.

Methods

We included 255 patients with PCR-confirmed primary SARS-CoV-2 infection and with a 30-day follow-up minimum. Blood samples were collected within the first 24 h of hospitalization to measure suPAR levels. Comprehensive data from medical records were analyzed to assess their predictive value in stratifying patients into seven severity groups, with groups 1 to 3 representing severe COVID-19 (death, intubation, ECMO, or non-invasive ventilation).

Results

Early plasma suPAR levels were significantly associated with severe disease progression, as evidenced by ANOVA and logistic regression models, highlighting suPAR as a persistent predictive factor for unfavorable outcomes.

Conclusion

Our findings suggest that a single suPAR measurement, performed early after a positive PCR test for SARS-CoV-2, holds strong predictive value for patient outcomes. This biomarker, alongside pulse oximetry and CT scan results, could be instrumental in early patient triage during seasonal COVID-19 resurgences.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊